Eur Arch Otorhinolaryngol:通过互联网搜索检测腺样体肥大、鼻炎和过敏性鼻炎的流行病学的相关性

2021-07-04 AlexYang MedSci原创

腺样体肥大(AH)是儿童阻塞性睡眠呼吸暂停(OSA)最常见的原因。AH的发病机制尚不清楚,但它与许多因素有关,如吸烟、季节性过敏和呼吸道感染。之前的研究已经证实了AH和鼻窦炎之间的关系,针对AH的治疗

腺样体肥大(AH)是儿童阻塞性睡眠呼吸暂停(OSA)最常见的原因。AH的发病机制尚不清楚,但它与许多因素有关,如吸烟、季节性过敏和呼吸道感染。之前的研究已经证实了AH和鼻窦炎之间的关系,针对AH的治疗方法可以有效地治疗鼻窦炎。然而,有关AH和过敏性鼻炎(AR)之间关系的信息并不一致。一些学者认为AR会诱发AH,而另一些学者则认为两者之间没有关系,或者两者之间是负相关的。

近期,有研究人员通过互联网搜索,调查了腺样体肥大(AH)与鼻窦炎,以及AH与过敏性鼻炎(AR)之间的流行病学相关性

研究人员从百度指数(BI)中检索了2011年1月至2019年12月的中国互联网搜索查询数据。采用Spearman相关系数来检测AH、鼻窦炎和AR的搜索量之间的关联性。他们还收集了2020年前5个月的搜索数据,当时由于冠状病毒病在2019年的流行,中国实施了检疫隔离。然后,研究人员将搜索数据与2019年同期获得的数据进行比较,评估了隔离对AH和AR的影响。

结果表明,2011-2019年期间AH和鼻窦炎的搜索变化之间有统计学意义上的相关性(R=0.643,P<0.05)。然而,AH和AR之间的关系很弱(R=- 0.239,P<0.05),鼻窦炎和AR之间(R=- 0.022,P>0.05)并不相关。AH和鼻窦炎的月平均搜索量有很强的相关性(R=0.846,P<0.01),但AH和AR以及鼻窦炎和AR没有相关性(R=- 0.350,P>0.05;R=- 0.042,P>0.05)。在2020年的前5个月,AH和鼻窦炎的搜索量持续下降(隔离),而AR的搜索量在1-2月增加。

平均每个月的搜索量

综上所述,AH与鼻窦炎有流行病学关系,这与AR不同。公共集会的减少有效地减少了AH和鼻窦炎的发病率,但没有减少AR的发病率

原始出处:

Yingchao Yang , Xinyi Li , Qiang Ma et al. Detecting epidemiological relevance of adenoid hypertrophy, rhinosinusitis, and allergic rhinitis through an Internet search. Eur Arch Otorhinolaryngol. Jun 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047429, encodeId=f0a4204e4297b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 22 15:49:53 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079977, encodeId=e7b420e997721, content=<a href='/topic/show?id=38b685e0729' target=_blank style='color:#2F92EE;'>#腺样体肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85707, encryptionId=38b685e0729, topicName=腺样体肥大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Feb 27 18:49:53 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837960, encodeId=676f183e96030, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Feb 23 04:49:53 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274368, encodeId=32e712e4368cc, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411389, encodeId=6ff5141138911, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996537, encodeId=991399653e6d, content=有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/f645756269ba45cba20b74d86f6e4d05/b0a88b1bdfc44cb79e79818ce296dbb9.jpg, createdBy=c2c55519856, createdName=wml_guyue, createdTime=Mon Jul 05 21:06:19 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047429, encodeId=f0a4204e4297b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 22 15:49:53 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079977, encodeId=e7b420e997721, content=<a href='/topic/show?id=38b685e0729' target=_blank style='color:#2F92EE;'>#腺样体肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85707, encryptionId=38b685e0729, topicName=腺样体肥大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Feb 27 18:49:53 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837960, encodeId=676f183e96030, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Feb 23 04:49:53 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274368, encodeId=32e712e4368cc, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411389, encodeId=6ff5141138911, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996537, encodeId=991399653e6d, content=有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/f645756269ba45cba20b74d86f6e4d05/b0a88b1bdfc44cb79e79818ce296dbb9.jpg, createdBy=c2c55519856, createdName=wml_guyue, createdTime=Mon Jul 05 21:06:19 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047429, encodeId=f0a4204e4297b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 22 15:49:53 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079977, encodeId=e7b420e997721, content=<a href='/topic/show?id=38b685e0729' target=_blank style='color:#2F92EE;'>#腺样体肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85707, encryptionId=38b685e0729, topicName=腺样体肥大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Feb 27 18:49:53 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837960, encodeId=676f183e96030, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Feb 23 04:49:53 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274368, encodeId=32e712e4368cc, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411389, encodeId=6ff5141138911, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996537, encodeId=991399653e6d, content=有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/f645756269ba45cba20b74d86f6e4d05/b0a88b1bdfc44cb79e79818ce296dbb9.jpg, createdBy=c2c55519856, createdName=wml_guyue, createdTime=Mon Jul 05 21:06:19 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047429, encodeId=f0a4204e4297b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 22 15:49:53 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079977, encodeId=e7b420e997721, content=<a href='/topic/show?id=38b685e0729' target=_blank style='color:#2F92EE;'>#腺样体肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85707, encryptionId=38b685e0729, topicName=腺样体肥大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Feb 27 18:49:53 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837960, encodeId=676f183e96030, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Feb 23 04:49:53 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274368, encodeId=32e712e4368cc, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411389, encodeId=6ff5141138911, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996537, encodeId=991399653e6d, content=有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/f645756269ba45cba20b74d86f6e4d05/b0a88b1bdfc44cb79e79818ce296dbb9.jpg, createdBy=c2c55519856, createdName=wml_guyue, createdTime=Mon Jul 05 21:06:19 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047429, encodeId=f0a4204e4297b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 22 15:49:53 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079977, encodeId=e7b420e997721, content=<a href='/topic/show?id=38b685e0729' target=_blank style='color:#2F92EE;'>#腺样体肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85707, encryptionId=38b685e0729, topicName=腺样体肥大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Feb 27 18:49:53 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837960, encodeId=676f183e96030, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Feb 23 04:49:53 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274368, encodeId=32e712e4368cc, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411389, encodeId=6ff5141138911, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996537, encodeId=991399653e6d, content=有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/f645756269ba45cba20b74d86f6e4d05/b0a88b1bdfc44cb79e79818ce296dbb9.jpg, createdBy=c2c55519856, createdName=wml_guyue, createdTime=Mon Jul 05 21:06:19 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-06 xugumin
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047429, encodeId=f0a4204e4297b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 22 15:49:53 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079977, encodeId=e7b420e997721, content=<a href='/topic/show?id=38b685e0729' target=_blank style='color:#2F92EE;'>#腺样体肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85707, encryptionId=38b685e0729, topicName=腺样体肥大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Feb 27 18:49:53 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837960, encodeId=676f183e96030, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Feb 23 04:49:53 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274368, encodeId=32e712e4368cc, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411389, encodeId=6ff5141138911, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Jul 06 04:49:53 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996537, encodeId=991399653e6d, content=有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/f645756269ba45cba20b74d86f6e4d05/b0a88b1bdfc44cb79e79818ce296dbb9.jpg, createdBy=c2c55519856, createdName=wml_guyue, createdTime=Mon Jul 05 21:06:19 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-05 wml_guyue

    有用的

    0

相关资讯

Allergy Asthma Clin Immunol:牛磺酸通过调节IL-35/STAT1途径促进过敏性鼻炎模型中CD4 + CD25 + FOXP3 + Treg细胞的产生

过敏性鼻炎(AR)是全世界最普遍的免疫性疾病之一。然而,常见的治疗方法往往有很大的副作用,或者对大多数人来说费用过高。大量的治疗方法已用于治疗AR,包括抗组胺药、类固醇和免疫调节剂。在这些治疗方法中,

盘点:近期鼻炎与治疗进展(八)

【1】Ann Allergy Asthma Immunol:SLIT片剂治疗过敏性鼻炎的进展分析

梅斯呼吸疾病进展(004期)

往期参见:梅斯呼吸疾病进展(第003期)

Allergy Asthma Clin Immunol:暴露于黑碳和花粉过敏原的鼻腔上皮细胞的转录组变化

空气污染可能与过敏性鼻炎(AR)中气道对过敏原的反应性增加有关。臭氧老化环境黑碳(O3BC)是大气颗粒物(PM)的一个重要组成成分,其对过敏性鼻炎的影响机制尚未完全阐明。

Eur Arch Otorhinolaryngol:Ectoin ®鼻炎喷雾剂与赛洛唑啉作为急性鼻炎治疗方案的比较

鼻窦炎是一种非常普遍的疾病,对患者的生活质量(QoL)有显著的负面影响,并造成社会经济负担。根据《欧洲鼻炎和鼻息肉意见书》(EPOS 2012),鼻窦炎定义为鼻子和副鼻窦的炎症,有两个或更多的症状,其

盘点:近期鼻部疾病研究进展(八)

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与